Field & Main Bank’s AstraZeneca AZN Stock Holding History

Field & Main Bank’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-47	Closed	-$6K	–	260
2022 Q2	$6K	Buy	+47	New	+$6.17K	﹤0.01%	266

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Field & Main Bank's AZN Position: Q3 2022 in Review

Field & Main Bank sold out of AstraZeneca (AZN) in Q3 2022, closing a stake of 47 shares — an estimated $6K sold.

Field & Main Bank first reported a position in AZN in Q2 2022 and held it in 1 quarter. The position peaked at $6K in Q2 2022. 965 funds tracked by Wall St. Rank hold AZN as of Q3 2022.

Field & Main Bank reported no remaining AstraZeneca position as of Q3 2022 after selling out during the quarter.
Field & Main Bank sold 47 AstraZeneca shares in Q3 2022, an estimated $6K.
Field & Main Bank first reported a position in AstraZeneca in Q2 2022 and held it in 1 quarter.
Field & Main Bank's AstraZeneca position peaked at $6K in Q2 2022.
965 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2022.

Based on Field & Main Bank's 13F filing for Q3 2022, filed 25 Oct 2022.